Announcement • Jul 15
Paxman Expands Global Regulatory Certifications for Cryocompression Device for Prevention of Chemotherapy-Induced Peripheral Neuropathy Paxman announced a series of significant regulatory milestones that strengthen its global quality management framework, supporting the forthcoming commercialisation of its expanded cryotherapy device portfolio to manage chemotherapy-induced side effects. Paxman has successfully extended the scope of its UK Conformity Assessed (UKCA), European Conformity (CE), International Organization for Standardization (ISO) 13485 and Medical Device Single Audit Program (MDSAP) certifications to include its new cryocompression technology for the management of chemotherapy-induced peripheral neuropathy (CIPN). The extended scope fulfils certification requirements in the UK and the EU and represent a key milestone toward approvals in Australia, Brazil, Canada, Japan and the United States for Paxman’s next-generation cryotherapy devices for managing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced alopecia (CIA). These certifications strengthen the Company’s global regulatory position, and mark a critical step in Paxman’s strategy to expand access to innovative cooling technologies designed to mitigate the side effects of chemotherapy, supporting patients globally. Paxman’s solution for preventing CIPN delivers both controlled cooling and compression to the hands and feet before, during, and after chemotherapy infusion, making it a unique and differentiated product in the market. Reported Earnings • May 22
First quarter 2026 earnings released First quarter 2026 results: Revenue: kr91.0m (up 31% from 1Q 2025). Net loss: kr125.0k (loss narrowed 98% from 1Q 2025). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Robert Kelly was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 20
Paxman AB (publ) to Report Q1, 2026 Results on May 21, 2026 Paxman AB (publ) announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on May 21, 2026 Announcement • Apr 21
Paxman AB (publ), Annual General Meeting, May 22, 2026 Paxman AB (publ), Annual General Meeting, May 22, 2026, at 10:00 W. Europe Standard Time. Location: minnesota conference venue, pirgatan 6, 374 35 karlshamn, sweden, Sweden Announcement • Feb 23
Paxman AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026 Paxman AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 27, 2026 Announcement • Feb 21
Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy Paxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT®? codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: The three-code structure mirrors the established coding framework for Paxman's FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement. During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN - a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients' quality of life. In October, The Paxman Neuropathy system was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA. Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027. Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN. Announcement • Jan 02
Paxman Announces 510k Submission to the U.S. Food and Drug Administration for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral Neuropathy PAXMAN announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the 510k Submission for the Paxman cryocompression device to prevent chemotherapy-induced peripheral neuropathy (CIPN). A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective. This follows the news in October, that the Paxman device, was accepted into the US FDA's Safer Technologies Program (STeP), and additionally, confirmation that the Category III CPT Code Application for the device, submitted to the American Medical Association (AMA) in November, is to be included on the Proposed Agenda for the February 2026 CPT®? Editorial Panel Meeting. These steps mark significant milestones in Paxman's regulatory pathways towards FDA clearance of this new technology. Product launches in select markets are currently being planned for 2026 with launch to all markets anticipated in 2027. More information regarding timelines will be communicated in the New Year. Announcement • Oct 20
PAXMAN Announces Acceptance of Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program PAXMAN announced that the U.S. Food and Drug Administration (FDA) has accepted the Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program (STeP). The FDA's Safer Technologies Program ("STeP") is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions. Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman's regulatory pathways towards FDA clearance of this new technology. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients. Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy. Announcement • Apr 17
Paxman AB (publ), Annual General Meeting, May 16, 2025 Paxman AB (publ), Annual General Meeting, May 16, 2025, at 10:00 W. Europe Standard Time. Location: at meeting hall zambesi, netport, biblioteksgatan 4, karlshamn, Sweden Announcement • Apr 08
Paxman AB (Publ) Elects Peter Mattisson as Chairman Paxman AB (publ) announced that Company held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman. Announcement • Mar 22
Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million. Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,900,000
Price\Range: SEK 65
Transaction Features: Subsequent Direct Listing Announcement • Mar 21
Paxman AB (publ) has filed a Follow-on Equity Offering. Paxman AB (publ) has filed a Follow-on Equity Offering.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,900,000
Transaction Features: Subsequent Direct Listing Announcement • Mar 19
Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc and others for Approximately SEK 150 million. Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc. and others for Approximately SEK 150 million on March 18, 2025. As part of acquisition, Paxman AB will acquire all shares in Dignitana AB. As part of consideration, Paxman AB will issue 2.5 million newly issued shares at a ratio of 0.030744 per common equity of Dignitana AB (publ). The merger between Paxman and Dignitana creates a New Group which provides clear synergies through increased revenues and reduced costs through rationalization but also economies of scale. Upon completion of the Offer, the shareholders of Paxman will own approximately 88.5% of the votes and capital and the shareholders of Dignitana will own approximately 11.5% of the votes and capital of the New Group. Agartha AB, which controls approximately 29.8% of the total number of outstanding shares and votes in Dignitana, supports and has undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or around April 14, 2025 and end on or around May 5, 2025, with payment of consideration expected to be made on or around May 13, 2025. In the event that Paxman, in connection with the Offer or otherwise, becomes the owner of shares corresponding to more than 90% of the shares in Dignitana, Paxman intends to call for compulsory acquisition in accordance with the Swedish Companies Act (2005:551) in order to acquire all outstanding shares in Dignitana. In connection therewith, Paxman intends to promote the delisting of Dignitana's shares from Nasdaq First North.
The transaction is subject to Offer being accepted to the extent that Paxman becomes the owner of the equivalent of more than 90% of all outstanding shares in Dignitana, approval of the shareholders of Paxman at the extraordinary general meeting of Paxman AB, all necessary authorizations, approvals, decisions and other measures for the Offer and the acquisition of Dignitana are obtained on terms acceptable to Paxman, including approvals from the Inspectorate of Strategic Products and the corresponding authorities in the United Kingdom and Italy. The Offer has been preceded by Paxman conducting a limited due diligence review of Dignitana of a confirmatory nature. The expected completion of the transaction is May 5, 2025.
Advokatfirman Delphi KB acted as legal advisor to Paxman AB. Bergs Securities AB acted as financial advisor and issuing agent to Paxman AB. Advokatfirman Vinge KB act as legal advisor to Dignitana AB. Stockholm Corporate Finance AB act as financial advisor to Dignitana AB. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €5.68, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 136% over the past year. New Risk • Oct 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €90.6m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Sep 19
Now 21% undervalued Over the last 90 days, the stock has risen 28% to €5.00. The fair value is estimated to be €6.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 6.0% in a year. Earnings are forecast to grow by 121% in the next year. Reported Earnings • Aug 22
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr65.8m (up 23% from 2Q 2023). Net income: kr9.82m (up 91% from 2Q 2023). Profit margin: 15% (up from 9.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €4.67, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 74% over the past year. New Risk • Jun 07
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Market cap is less than US$100m (€79.6m market cap, or US$86.7m). Announcement • May 24
Paxman AB (publ) Appoints Karen Giddings Clakely to the Board PAXMAN´s AGM held on 23 May 2024, appointed Karen Giddings Clakely to the board. Recent Insider Transactions • Dec 16
Director recently sold €275k worth of stock On the 12th of December, Glenn Paxman sold around 100k shares on-market at roughly €2.75 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €310k more than they bought in the last 12 months. Reported Earnings • Nov 19
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr63.4m (up 46% from 3Q 2022). Net income: kr7.36m (up 58% from 3Q 2022). Profit margin: 12% (in line with 3Q 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. New Risk • Aug 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr31m). Market cap is less than US$100m (€54.8m market cap, or US$59.1m). Reported Earnings • May 25
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr45.7m (up 54% from 1Q 2022). Net loss: kr2.53m (loss narrowed 59% from 1Q 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Breakeven Date Change • Feb 26
Forecast to breakeven in 2023 The analyst covering Paxman expects the company to break even for the first time. New forecast suggests the company will make a profit of kr16.0m in 2023. Earnings growth of 119% is required to achieve expected profit on schedule. Announcement • Jan 28
Paxman Scalp Cooling System Receives EU MDR Certification Paxman has received EU Medical Device Regulation (MDR) certification from its Notified Body, the British Standards Institution (BSI). The Medical Device Directive 93/45/EEC was introduced in 1993 and there were no changes to the legislation until the significant shift to Medical Device Regulations 2017/745 in 2021, with aim being to modernize and create a robust and long-term legislative framework, with strict inspection by Notified Bodies to ensure the levels of safety. The introduction of the MDR 2017/745 means more stringent requirements, particularly in clinical and post-market review data. As a result, Paxman, along with many medical device companies within the EU, have had to make significant time and financial investments to improve processes to capture and analyse the data required to continue trading in the European Union. Since submission of Paxman’s initial application for MDR in 2019, the Technical & Quality Department have effected extensive changes to the technical files within the Quality Management System (QMS) to comply with the new regulations including a full QMS audit, Clinical Evaluation review and extensive Technical Documentation review. Reported Earnings • Nov 19
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr43.4m (up 74% from 3Q 2021). Net income: kr4.65m (up kr9.90m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. CEO & Director Richard Paxman was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 25
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr38.5m (up 52% from 2Q 2021). Net income: kr600.0k (up kr6.07m from 2Q 2021). Profit margin: 1.6% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Reported Earnings • May 26
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr29.7m (up 30% from 1Q 2021). Net loss: kr6.21m (loss widened kr5.48m from 1Q 2021). Recent Insider Transactions • Apr 29
Director recently sold €530k worth of stock On the 21st of April, Glenn Paxman sold around 100k shares on-market at roughly €5.30 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. CEO & Director Richard Paxman was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Mar 04
Paxman AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023 Paxman AB (publ) announced that they will report fiscal year 2022 results on Feb 24, 2023 Reported Earnings • Feb 27
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: kr0.72 loss per share (up from kr1.20 loss in FY 2020). Revenue: kr104.7m (up 26% from FY 2020). Net loss: kr12.8m (loss narrowed 33% from FY 2020). Revenue exceeded analyst estimates by 1.2%. Board Change • Feb 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. CEO & Director Richard Paxman was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
